What could you do if your data was working for you and not against you? With Bloomberg delivering

enterprise data directly to your systems, you get easy access to the details you want, optimized for

higher level analysis, and financial data experts committed to helping you maximize your every move.

Our data is made for more, so you can show the world what you're made of.

Visit Bloomberg.com slash enterprise data to learn more.

Welcome to Prognosis. I'm Laura Carlson. It's day 177 since coronavirus was declared a global pandemic.

Today's main story,

the pandemic has plunged the world into a global recession.

But what does a post-COVID economy look like?

But first, here's what happened in virus news today.

Scientists at the University of Washington forecast that deaths from COVID-19 in the U.S. are likely to more than double by the end of the year.

The researchers predicted that the death toll would reach 410,000 by January 1, 2021.

But, they said, that number could be cut dramatically with certain precautions.

If almost everyone wears masks and governments with high death rates put social distancing measures in place, more than 100,000 deaths could be prevented in the U.S., and 770,000 lives could be saved worldwide.

Danish drug maker Novo Nordisk is exploring whether a new class of medicines

that helps people lose weight and control diabetes also has potential in fighting COVID-19.

Research shows people afflicted by obesity and diabetes often fare worse with the disease.

Now, new data shows GLP1 drugs, which help patients keep blood sugar levels in check,

could be a meaningful therapy in helping people

with diabetes battle COVID-19, according to Novo chief scientific officer Mads Krogsgard Thompson.

He pointed to evidence the virus attacks cells that produce the hormone insulin.

Finally, the first peer-reviewed data on Russia's proposed COVID-19 vaccine show it has promise.

...